Activation of the serine/theronine protein kinase akt in enteropancreatic neuroendocrine tumors

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 5063-5068

  Ghayouri, Masoumeh ^a   Boulware, David ^b   Nasir, Aejaz ^b   Strosberg, Jonathan ^b   Kvols, Larry ^b   Coppola, Domenico ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Immunohistochemistry; Neuroendocrine tumors; P Akt

Indexed keywords

PROTEIN KINASE B;

ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; METASTASIS; NEUROENDOCRINE TUMOR; PANCREAS; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; DIGESTIVE SYSTEM NEOPLASMS; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 78751518847     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Jensen RT and Doherty GM: Carcinoid tumors and the carcinoid syndrome. In: Cancer: Principle and Practice of Oncology, De Vita VT Jr., Hellman S, Rosenberg SA (eds). Philadelphia: Lippincott Williams & Wilkins, 2005.
2. Kulke MH and Raut CP: Neuroendocrine tumors of the gastrointestinal tract. In: Principle and Practice of Gastrointestinal Oncology. Kelsen DP et al. (eds.). Philadelphia, USA: Lippincott Williams & Wilkins, pp. 653-692, 2008.
3. Khanna G, Bushneil D and O'Dorisio MS: Utility of radiolabeled somatostatin receptor analogues for staging/restaging and treatment of somatostatin receptor-positive pediatric tumors. Oncologist 13: 382-389, 2008
4. Christofori G, Naik P and Hanahan D: Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 9: 1760-1770, 1995.
5. La Rosa S, Chiaravalli AM, Capella C, Uccella S and Sessa F: Immuno-histochemical localization of acidic fibroblast growth factor in normal human enterochromaffin cells and related gastrointestinal tumours. Virchows Arch 430: 117-124, 1997.
6. Nilsson O, Wangberg B, Kolby L, Schultz GS and Ahlman H: Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours. Int J Cancer 60: 645-651, 1995.
7. Chaudhry A, Oberg K, Gobi A, Heldin CH and Funa K: Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. Anticancer Res 14: 2085-2091, 1994.
8. Krishnamurthy S and Dayal Y: Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in gastrointestinal carcinoids. Am J Surg Pathol 21: 327-33, 1997. (Pubitemid 27120202)
9. Chaudhry A, Papanicolaou V, Oberg K, Heldin CH and Funa K: Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res 52: 1006-1012, 1992.
10. Van Gompel JJ and Chen H: Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells. Surgery 136: 1297-1302, 2004. (Pubitemid 39647548)
11. Höpfner M, Baradari V, Huether A, Schöfl C and Scherübl H: The insulin-like growth factor receptor I is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr Relat Cancer 13: 135-149, 2006.
12. Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP and Caplin ME: Epidermal growth factor receptor expression and activation in neuroendocrine tumors. J Neurendocrinol 18: 355-360, 2006.
13. La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F and Capella C: Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol 34: 18-27, 2003. (Pubitemid 36160017)
14. Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A and Slavin S: The Israel Glivec in Solid Tumors Study Group. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 13: 535-540, 2006.
15. Chen H, Kunnimalaiyaan M and Van Gompel JJ: Medullary: Thyroid cancer: The functions of raf-1 and human achaete-scute homologue-1. Thyroid 15: 511-521, 2005.
16. Kunnimalaiyaan M, Traeger K, Chen H: Conservation of the Notchl signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 259: G636-G642, 2005.
17. Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M, Hsiao EC, Schuebel KE, Borges MW, Jin N, Collins BJ, Nelkin BD, Chen H and Ball DW: Regulation of neuroendocrine differentiation in gastointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab 90: 4350-4356, 2005.
18. Zikusoka, MN, Kidd M, Eick G, Latich I and Modlin IM: The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 104: 2292-2309, 2005.
19. Kunnimalaiyaan M, Ndiaye M and Chen H: Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways. Surgery 142: 959-964, 2007.
20. Vignot S, Faivre S, Aguirre D and Raymond E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16: 525-537, 2005.
21. Kunnimalaiyaan M, Yan S, Wong F, Zhang YW and Chen H: Hairy Enhancer of Split-1 (HES-1), a Notchl effector, inhibits the growth of carcinoid tumor cells. Surgery 138: 1137-1142, 2005. (Pubitemid 41797355)
22. Lankat-Buttgereit B, Horsch D, Barth P, Arnold R, Blocker S and Goke R: Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. Digestion 71: 131-140, 2005.
23. Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SB and Ball DW: Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 61: 3200-3205, 2001.
24. Wang L, Ignat A and Axiotis CA: Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl Immunohistochem Mol Morphol 10: 139-146, 2002.
25. Charland S, Boucher MJ, Houde M and Rivard N: Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology 142: 121-128, 2001. (Pubitemid 32183673)
26. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and González-Barón M: PI3K7Akt signaling pathway and cancer. Cancer Treat Rev 30: 193-204, 2004.
27. Osahi M, Oshimura M and Ito H: PI3K-Akt pathway: Its function and alternations in human cancer. Apotosis 9: 667-676, 2004.
28. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signaling controls tumor cell growth. Nature 441: 424-430, 2006.
29. Shiojimo I and Walsh K: Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 90: 1243-1250, 2002. (Pubitemid 34787405)
30. Datta Sr., Brunet A and Greenberg ME: Cellular survival: a play in three Akts. Genes Dev 1513: 2905-2227, 1999.
31. Pitt SC, Chen H and Kunnimalaiyaan M: Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors. Ann Surg Oncol 16(10): 2936-2942, 2009.
32. Kunnimalaiyaan M, Ndiaye M and Chen H: Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery 140: 1009-1015, 2006.
33. Smolewski P: Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 17: 487-494, 2006.
34. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L and Oza A: A phase II clinical trial and pharmacodynamic study of temsirolimus in advanced nuroendocrine carcinomas. Br J Cancer 95: 1148-1154, 2006.
35. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC and Meric-Bernstam F: Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 15: 257-266, 2008.
36. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, Pagotto U and Stalla GK: Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zacl expression. Cancer Res 66: 1576-1582, 2006.
37. Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A Jr., Dálino P, Salahuddin N, Korbonits M and Grossman AB: Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neurendocrinol 57: 168-181, 2008.